3070 Bristol Pike, Suite 112, Bensalem, PA 19020
Call Us: (215) 638-4847 |
Fax: (215) 638-4867
This investigation is for anyone who acquired securities in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to October 31, 2024.
The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by fraudulently inflating Medicare reimbursement rates for Eylea by knowingly submitting false average sales price reports to the Centers for Medicare and Medicaid Services.
On April 10, 2024, the US Department of Justice (“DOJ”) announced that it had filed a complaint against Regeneron under the False Claims Act alleging that the Company fraudulently inflated Medicare reimbursement rates for Eylea by knowingly submitting false average sales price reports to the Centers for Medicare and Medicaid Services that excluded certain price concessions. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting “U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.” The Company also revealed that “[n]et product sales of EYLEA in the third quarter of 2024 were adversely impacted by a lower net selling price compared to the third quarter of 2023.” In the wake of this news, Reuters reported the Company had “reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea.” On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.
The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to October 31, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.
Copyright © 2024 The Law Offices of Howard G. Smith. All Rights Reserved.